(Q41489984)

English

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

scientific article published on 13 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 October 2017

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). (English)

1 reference

Europe PubMed Central

1 October 2017

1 reference

based on heuristic

inferred from title

Herbert Kim Lyerly

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

X Wang

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

J Ren

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

J Zhang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Y Yan

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

N Jiang

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

J Yu

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

L Di

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

G Song

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

L Che

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

J Jia

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

X Zhou

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

H Yang

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

13 August 2015

1 reference

Europe PubMed Central

1 October 2017

Clinical and Translational Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

82-87

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26266766%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

https://scigraph.springernature.com/pub.10.1007/s12094-015-1339-2

0 references

Updates in the treatment of basal/triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

The management of early-stage and metastatic triple-negative breast cancer: a review

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Anti-PD-L1 for metastatic triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Triple-negative breast cancer: are we making headway at least?

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

High-dose chemotherapy of cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation as a consolidation for breast cancer patients with 10 or more positive lymph nodes: a 5-year follow-up results

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1339-2

21 January 2018

Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26266766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/26266766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant treatments for triple-negative breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/26266766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current treatment options in triple negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26266766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on triple-negative breast cancer: prognosis and management strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/26266766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41489984&oldid=1568129557"